ACE and atherosclerosis: Due to the fact that patients in the HOPE and EUROPA trials suspectedly had more advanced atherosclerosis, it is possible that the role in improving the prognosis of ACE inhibitor might be less important in patients at lower cardiovascular risk and without overt coronary heart disease [20].